97 Compared to other reference groups receiving non-GLP-1RAs drugs or no treatment, a study including 168 women, who took any one of the GLP-1RAs throughout the first trimester for diabetes or obesity-related illnesses, revealed no increased risk of birth abnormalities or congenital malformations, scoring a value of 2.3%, which aligns with the European Surveillance of Congenital Anomalies value of 2.6%
Ethnopharmacological knowledge can guide the design of synergistic phytochemical combinations that move beyond single compound interventions toward standardized multi component formulations with complementary actions on redox balance, membrane biology, and immune modulation (Yang et al., 2020)
Intell Pharm
When I tell a patient I want to delay their surgery to correct a nutritional deficiency, it is rarely welcome news
Sub-cultivation was performed every 35 d
Starting on a lower dose and gradually increasing it may also reduce symptoms